<DOC>
	<DOC>NCT01121666</DOC>
	<brief_summary>Ther purpose of this study is to show equivalence between AFOLIA and Gonal-f® with regard to the number of oocytes retrieved in women for assisted reproductive treatment.</brief_summary>
	<brief_title>Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Age between 20 and 38 years with regular menstrual cycles of 2535 days First or second cycle in the present series of ART BMI ≥ 18 ≤ 30 kg/m2 Basal FSH &lt; 10 IU/L (cycle day 25) E2 levels &lt; 50pg/mL (&lt; 0.18 nmol/L) at the day of FSH administration Antral follicle count (AFC) ≥ 10 to ≤ 25 follicles (sum of both ovaries) Infertility due to any of the following factors: tubal factor, mild endometriosis (ASRM stage 12), male factor, unexplained infertility Presence of both ovaries and normal uterine cavity (confirmed by transvaginal ultrasound within 6 months before randomisation) Willingness to participate in the study and to comply with the study protocol Informed consent Presence of pregnancy History of ≥2 succeeding ART cycles (IVF and/or ICSI) before the study cycle without clinical pregnancy Presence of clinically significant systemic disease Presence of chronic cardiovascular, hepatic, renal or pulmonary disease Presence of uncontrolled endocrine disorder Previous history or presence of severe ovarian hyperstimulation syndrome Presence of polycystic ovaries (PCO) Presence of severe endometriosis (ASRM stage 3 or stage 4) and hydrosalpinx Neoplasia, including tumors of the hypothalamus and pituitary gland Abnormal bleeding of undetermined origin History of poor response to gonadotropin treatment (defined as fewer than 5 oocytes retrieved in a previous attempt) Male infertility without mobile spermatozoa in the ejaculate, that need testicular of epididymal sperm retrieval (MESA/TESE/TESA) Endocrine abnormality such as TSH or prolactin level elevations outside the reference range if clinically relevant at screening Any hormonal treatment within 1 month before the start of the FSH treatment (with the exception of levothyroxin) History of drug, nicotine or alcohol abuse within the last 12 months (&gt; 10 cigarettes/day) Administration of other investigational products within the last month Clinically abnormal findings at Visit 1 Planned PGS/PGD/PBB or assisted hatching Concomitant participation in an other study protocol History of extrauterine pregnancy in the previous 3 months Known allergy or hypersensitivity to progesterone or to any of the excipients (including peanut oil) of the additional study medication (GnRH agonist, vitrelle®, and Utrogestan®) Presence or history of thrombophlebitis or thromboembolic disorders Presence or history of cerebral haemorrhage Presence or history of porphyria</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Assisted reproductive treatment</keyword>
	<keyword>Superovulation</keyword>
	<keyword>Follitropin alfa</keyword>
	<keyword>r-hFSH</keyword>
	<keyword>AFOLIA</keyword>
</DOC>